News Sentiment

OSUR sentiment intelligence

OraSure Technologies Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 50 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Medical Instruments & Supplies Read-through group
Latest close 4.30 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

84/100 classification confidence.

Company focus 50

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

-1.3% over one week, +2.8% over four weeks, trend active, and near fair-value range.

Latest direct headline Positive

OraSure Technologies stock holds steady as diagnostics business targets growth

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 84/100 classification
One-week reaction -1.3% Price digesting
Trend fit Trend active 2.8% over four weeks
Fair value 0.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 31
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 50
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
TradingView 7
Stock Titan 5
dars.gov.et 4
TradingKey 4
Reuters 4
DonanımHaber 3
Investing.com 3
Ad-hoc-news.de 2

Event Lens

What the news is about

Classified themes
Market update 34
Earnings 13
Macro sensitivity 1
Balance sheet 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 50
Ad-hoc-news.de Direct company coverage

OraSure Technologies stock holds steady as diagnostics business targets growth

OraSure Technologies (OSUR) is a Nasdaq-listed diagnostics and life-sciences company focusing on rapid infectious disease testing and molecular solutions. The company's business model combines consumables-driven testing with a growing molecular solutions segment, catering to both

Tone
Positive 66/100
Event
Market update
Published
09 Jul 2026 17:42
Source
Ad-hoc-news.de
Ad-hoc-news.de Direct company coverage

OraSure Technologies updates highlight diagnostics focus amid shifting health trends

OraSure Technologies is focusing on its diagnostics and sampling portfolio, adapting to evolving demand for infectious-disease and at-home testing. The company, known for its rapid tests like OraQuick, aims to retain customers and launch new products as pandemic-driven demand nor

Tone
Neutral 50/100
Event
Macro sensitivity
Published
03 Jul 2026 11:09
Source
Ad-hoc-news.de
Investing.com Canada Direct company coverage

Form 4 OraSure Technologies Inc For: 30 June By Investing.com

This article reports on the filing of Form 4 by OraSure Technologies Inc for the period ending June 30. Form 4 is a document that must be filed with the SEC whenever there is a material change in the holdings of company insiders. The article indicates that OraSure Technologies In

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 04:40
Source
Investing.com Canada
Stock Titan Direct company coverage

OraSure Technologies (OSUR) director takes 3,666-share stock grant in lieu of cash

OraSure Technologies director Steven Kyle Boyd received a grant of 3,666 restricted shares of common stock, valued at $4.4325 per share, in lieu of cash director fees. This transaction, processed under the company's Stock Award Plan, immediately vested and increased Boyd's direct

Tone
Positive 64/100
Event
Balance sheet
Published
01 Jul 2026 03:40
Source
Stock Titan
Finviz Direct company coverage

OSUR - Orasure Technologies Inc Latest SEC Filings

This article provides detailed financial data and performance metrics for Orasure Technologies Inc (OSUR) as of June 30. It includes information on market capitalization, sales, income, various ratios, insider and institutional ownership, and stock performance over different peri

Tone
Neutral 50/100
Event
Market update
Published
01 Jul 2026 03:40
Source
Finviz
TradingView Direct company coverage

Enterprise value to EBIT forward of OraSure Technologies, Inc. – MUN:EP3

The article focuses on the enterprise value to EBIT forward of OraSure Technologies, Inc. (MUN:EP3). It provides a high-level overview of the company's financial data on TradingView, listing it under Health Technology and Medical Specialties on the Munich Stock Exchange. The page

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 22:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of OraSure Technologies, Inc. – NASDAQ:OSUR

This article provides a financial overview of OraSure Technologies, Inc. (NASDAQ: OSUR), focusing on its forward price-to-earnings ratio. It seems to be a placeholder or a stub page from a financial data provider, as it primarily lists navigation and platform features rather than

Tone
Neutral 50/100
Event
Earnings
Published
29 Jun 2026 05:14
Source
TradingView
TradingView Direct company coverage

Price to book forward of OraSure Technologies, Inc. – NASDAQ:OSUR

The article presents the "Price to book forward" financial metric for OraSure Technologies, Inc. (NASDAQ: OSUR). It is a brief data point provided by TradingView, indicating a specific financial value for the company within a given period.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 11:09
Source
TradingView
TradingView Direct company coverage

Price to book forward of OraSure Technologies, Inc. – LSX:881351

This page from TradingView provides financial information for OraSure Technologies, Inc. (LSX:881351), specifically focusing on its price-to-book forward ratio. The content indicates that the market is currently closed and shows no recent trades for the company.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 10:40
Source
TradingView
TradingView Direct company coverage

Price to sales forward of OraSure Technologies, Inc. – LSX:881351

The article focuses on the "Price to sales forward" metric for OraSure Technologies, Inc. (LSX:881351) as of June 27, 2026. It appears to be a financial data snippet from a larger platform, indicating the company's valuation based on its forward sales. No specific financial figur

Tone
Neutral 50/100
Event
Market update
Published
27 Jun 2026 02:39
Source
TradingView
TradingView Direct company coverage

Price to sales forward of OraSure Technologies, Inc. – NASDAQ:OSUR

The article displays the "Price to sales forward" metric for OraSure Technologies, Inc. (NASDAQ: OSUR) within the TradingView platform. It shows the period, value, change, and percentage change for this financial metric, indicating that the market was closed with no trades at the

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 19:41
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of OraSure Technologies, Inc. – LSX:881351

The article focuses on the "Price to earnings forward" metric for OraSure Technologies, Inc. (LSX:881351) as listed on the Lang & Schwarz Exchange. It appears to be a financial data page from TradingView, indicating that the market was closed at the time of viewing. The content p

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:40
Source
TradingView
TradingKey Direct company coverage

OraSure Technologies Inc (OSUR) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of OraSure Technologies Inc (OSUR), detailing its price momentum, support and resistance levels, and various technical indicators. As of June 17, 2026, the stock has a price momentum score of 9.48, and its technical indicators and moving

Tone
Positive 71/100
Event
Market update
Published
17 Jun 2026 18:10
Source
TradingKey
TradingKey Direct company coverage

OraSure Technologies Inc (OSUR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for OraSure Technologies Inc (OSUR), detailing its current earnings forecast score, analyst ratings, and price targets. The company ranks 66 out of 203 in the Healthcare Equipment & Supplies industry with an average price target of $4.50

Tone
Positive 75/100
Event
Earnings
Published
17 Jun 2026 16:09
Source
TradingKey
TradingKey Direct company coverage

OraSure Technologies Inc (OSUR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a detailed revenue breakdown for OraSure Technologies Inc (OSUR), categorizing its revenue by business segments and geographic regions. The company's main revenue streams come from Net product and services in HIV, Microbiome, and HCV, with the United States

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 15:09
Source
TradingKey
TradingKey Direct company coverage

OraSure Technologies Inc (OSUR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides historical dividend and stock split information for OraSure Technologies Inc (OSUR). It indicates that the company has distributed a total of 0.00 USD in dividends over the past five years and contains no data for historical stock splits. The article also pr

Tone
Neutral 50/100
Event
Capital return
Published
16 Jun 2026 16:39
Source
TradingKey
Simply Wall Street Direct company coverage

OSUR: At-Home STI Testing Expansion Will Drive Bullish Long-Term Outlook

OraSure Technologies' (OSUR) analyst price target remains at $4.75, with its fair value unchanged despite slight adjustments to discount rate, profit margin, and future P/E assumptions. Key news includes FDA clearance for its Colli-Pee™•Dx Urine Collection Kit to expand at-home S

Tone
Positive 70/100
Event
Earnings
Published
14 Jun 2026 22:09
Source
Simply Wall Street
GlobeNewswire Direct company coverage

OraSure Technologies, Inc. Announces FDA Clearance that Expands Patient‑Friendly Access to Testing for Sexually Transmitted Infections

OraSure Technologies, Inc. announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, allowing at-home self-collection of urine samples for STI testing. This kit integrates with Roche's cobas® molecular diagnostic systems to detect Chlamydia trachomatis, Neisseria gonorr

Tone
Positive 74/100
Event
Market update
Published
12 Jun 2026 09:09
Source
GlobeNewswire
Investing.com Australia Direct company coverage

OraSure gets FDA nod for at-home STI urine collection kit By Investing.com

OraSure Technologies Inc. received FDA clearance for its Colli-Pee Dx Urine Collection Kit, enabling at-home STI sample collection for use with Roche's diagnostic tests. This development aims to increase accessibility and convenience for patients, contributing to OraSure's stock

Tone
Positive 71/100
Event
Market update
Published
12 Jun 2026 08:10
Source
Investing.com Australia
Investing.com Direct company coverage

OraSure gets FDA nod for at-home STI urine collection kit

OraSure Technologies Inc. has received FDA clearance for its Colli-Pee Dx Urine Collection Kit, allowing at-home sample collection for Roche's sexually transmitted infection tests. This development makes STI testing more accessible and convenient for patients. Despite the positiv

Tone
Positive 71/100
Event
Market update
Published
11 Jun 2026 20:40
Source
Investing.com
Lehigh Valley Business Direct company coverage

OraSure receives FDA clearance for home urine collection kit for STIs

OraSure Technologies Inc., based in Bethlehem, has announced that its subsidiary DNA Genotek Inc. received FDA clearance for its Colli-Pee•Dx Urine Collection Kit. This kit enables convenient at-home self-collection of first-void urine for STI testing, supporting various Roche di

Tone
Positive 76/100
Event
Market update
Published
11 Jun 2026 18:40
Source
Lehigh Valley Business
Stock Titan Direct company coverage

OraSure Technologies (NASDAQ: OSUR) wins FDA clearance for Colli-Pee Dx at-home urine collection kit

OraSure Technologies (NASDAQ: OSUR) has received FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, developed by subsidiary DNA Genotek Inc. This kit is designed for at-home self-collection of first-void urine and is compatible with Roche Molecular Systems tests for severa

Tone
Positive 78/100
Event
Market update
Published
11 Jun 2026 12:40
Source
Stock Titan
WFMZ.com Direct company coverage

OraSure secures FDA clearance for product seen as key to future growth

OraSure Technologies (NASDAQ: OSUR) has received FDA clearance for its Colli-Pee kit, an at-home urine collection device used for detecting sexually transmitted infections in conjunction with Roche's molecular diagnostic systems. This clearance is seen as crucial for the Bethlehe

Tone
Positive 73/100
Event
Market update
Published
11 Jun 2026 12:40
Source
WFMZ.com
Stock Titan Direct company coverage

FDA clears at-home urine kit that lets labs test for 4 STIs by mail

OraSure Technologies announced FDA clearance for its Colli-Pee™•Dx Urine Collection Kit, which allows at-home, first-void urine self-collection for testing of four common sexually transmitted infections (STIs) in conjunction with Roche's cobas® molecular diagnostic systems. This

Tone
Positive 70/100
Event
Market update
Published
11 Jun 2026 11:40
Source
Stock Titan
Investing.com Direct company coverage

OraSure stock jumps on FDA clearance for at-home STI kit

OraSure Technologies Inc. (NASDAQ:OSUR) shares jumped over 4% after receiving FDA clearance for its at-home urine collection kit for sexually transmitted infection (STI) testing. The kit, Colli-Pee Dx Urine Collection Kit, combines with Roche's molecular lab testing equipment to

Tone
Neutral 50/100
Event
Market update
Published
11 Jun 2026 09:24
Source
Investing.com